The PersTIgAN Consortium

The project strength the collaboration in multi-disciplinary network of scientists and physicians in both academic and industrial research.

Partners & Expertise:

P1 Hospital St. Georg gGmbH, Martin-Luther-Universität Halle/Wittenberg: Clinical expertise, access to human urine samples, General project idea, design, draft, writing of the clinical study protocol, approval with local (study lead) IRB, overall project coordination.

P2 Mosaiques Diagnostics GmbH: Proteome analysis using CE-MS-technology, establishing of database to store collected urine samples and all clinical data and clinical data application. P2 provides state of the art peptidomics profiling and clinical proteomics expertise.

P3 University of Toronto and Toronto General Research Institute: Clinical expertise, access to human urine samples, The Canadian GN Registry is a prospective cohort recruiting patients (including IgAN) from 8 sites across Canada, led by Dr. Reich. Launched in 2017 with CIHR support (SPOR program), this builds on an existing single centre database (Toronto Registry) established over 35 years ago. The framework used to establish the web-based data collection tool for the CGNR can be leveraged to develop the clinical data collection instrument used for the proposed project.

P4 Fundación Jiménez Díaz: Spanish IgAN registry patients and samples . The group has experience in systems biology identification and characterization of novel potential biomarkers and therapeutic targets and has identified potential urinary biomarkers of acute kidney injury to be tested in this project.

P5 Medical University Innsbruck: Extensive and well organized local biopsy registry including biomaterial such as serum, plasma, urine and tissues. Clinical database with electronic records since the year 2000 is also available. Our research lab has longstanding experience in biomarker research in body fluids and in renal tissue. We have participated and are still involved in multi-center studies with focus on biomarker discovery in chronic kidney diseases. Furthermore we performed systems biology analyses in the
prediction of renal function in diabetic nephropathy and in other proteinuric kidney diseases.

P6 Umea University: Swedish biopsy registry contact and inclusion, clinical patient inclusion and follow up contacts, collection of start and intermediate data and samples for evaluation, clinical study software data entering

Associated research partner:

Charles University in Prague: clinical expertise, access to human urine samples